Uncategorized
Detecting Disease at Its Molecular Origin
Sponsored content brought to you by

Even for most of modern medicine, the beginning of a disease is synonymous with symptoms. A patient forgets names. Blood sugar rises. Muscles weaken. Only then does diagnosis begin. At the molecular level, though, many diseases start much earlier—sometimes years before symptoms emerge.
Garage Brain Science (GBS), a Taiwan-based biotechnology company focused on asymptomatic-stage screening and intervention, is working to move medicine toward that earlier starting line. Its research focuses on detecting subtle molecular signals that appear before disease becomes clinically visible.
The company recently announced new clinical-research collaborations to support the development of two investigational rapid screening technologies, which might eventually be available for at-home testing. One targets early metabolic stress associated with prediabetes. The other focuses on structural abnormalities in a protein called TDP-43, which is strongly linked to several neurodegenerative diseases.
Together, these programs reflect a broader vision: identifying disease processes during the silent phase when the most effective intervention might still be possible.
Beyond traditional risk factors
Historically, preventive medicine emphasized population-level risks, such as smoking, obesity, or hypertension. Although important, these factors do not necessarily reveal whether disease processes have already begun inside the body.
Instead, GBS focuses on molecular signals—particularly protein misfolding and abnormal biomolecular condensation, such as an irregular clump of proteins. These processes can occur long before measurable physiological changes appear.

For metabolic disease, as an example, many conventional tests detect problems only after dysfunction has progressed. Common examples include measuring the percentage of hemoglobin in the blood that is bound to glucose—hemoglobin A1c (HbA1c) testing—or glucose levels in the blood after not eating—fasting blood-glucose testing. GBS’s investigational prediabetes screening strategy aims to identify earlier stress signals, including patterns associated with islet amyloid polypeptide (IAPP), a protein involved in pancreatic biology.
Initial feasibility work by GBS has been conducted using blood-based assays, and a prototype urine-based format has shown proof-of-concept for potential at-home screening.
Predicting neurodegeneration and more
TDP-43 (TAR DNA-binding protein 43) is a central focus of GBS’s neurodegeneration research. Under normal conditions, TDP-43 is involved in RNA processing and gene regulation and is primarily located in the cell nucleus. In several neurological diseases, however, the protein begins to behave abnormally.
TDP-43 can misfold, accumulate into aggregates, and shift from the nucleus into the cytoplasm of cells. These structural changes disrupt cellular function and are widely recognized as hallmarks of conditions including amyotrophic lateral sclerosis (ALS), certain forms of frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). All of these molecular abnormalities can develop long before patients experience noticeable neurological symptoms.
GBS is developing screening approaches designed to detect signals associated with TDP-43 structural abnormalities in biofluids, such as blood, aiming to move the evaluation of neurodegenerative risk further upstream.
Interpretable disease trajectories
Beyond individual assays, GBS is also building a broader analytical framework called Disease Origin, an AI-driven platform designed to interpret molecular condensation signatures across multiple proteins. Instead of generating a simple binary output, the platform is intended to integrate protein-pattern information with immune and metabolic context. In this framework, screening is not viewed as a one-time snapshot, but as part of a more structured view of disease trajectory, including whether follow-up might be warranted and when additional evaluation might be appropriate.
GBS hopes that combining multi-protein analysis with longitudinal monitoring will provide a clearer understanding of disease trajectories.
Rethinking when medicine begins
To support the development and validation of its technologies, GBS has initiated clinical collaborations with institutions including the National Taiwan University Hospital and the Mayo Clinic. The company is also planning regulatory pathways aligned with potential future deployment in the United States.
For now, the screening technologies remain investigational. Nonetheless, the broader scientific idea behind the work is gaining traction: diseases often begin years before symptoms appear. If those early molecular signals can be detected reliably, medicine might eventually shift from treating established illness to identifying disease at its earliest biological origin.

Learn more about AI-enabled asymptomatic medicine at bit.ly/3PmjxNp.
The post Detecting Disease at Its Molecular Origin appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.
The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”
The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”
Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.
The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”
Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.
“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”
“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”
The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Uncategorized
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
